Across TCGA pan-cancer cohorts, SUMO3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SUMO3 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher SUMO3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SUMO3 expression acts as an unfavorable survival marker.
KICH and UCEC are the cancer types where SUMO3 Mutation most reproducibly stratifies survival.